356 related articles for article (PubMed ID: 33099724)
1. Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer.
Voß H; Wurlitzer M; Smit DJ; Ewald F; Alawi M; Spohn M; Indenbirken D; Omidi M; David K; Juhl H; Simon R; Sauter G; Fischer L; Izbicki JR; Molloy MP; Nashan B; Schlüter H; Jücker M
Clin Exp Metastasis; 2020 Dec; 37(6):649-656. PubMed ID: 33099724
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
Kelm M; Schollbach J; Anger F; Wiegering A; Klein I; Germer CT; Schlegel N; Kunzmann V; Löb S
BMC Cancer; 2021 May; 21(1):490. PubMed ID: 33941104
[TBL] [Abstract][Full Text] [Related]
3. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
4. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
[TBL] [Abstract][Full Text] [Related]
5. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
7. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
9. [The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis].
Honjou H; Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2216-9. PubMed ID: 22202335
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
Baba K; Oshita A; Kohyama M; Inoue S; Kuroo Y; Yamaguchi T; Nakamura H; Sugiyama Y; Tazaki T; Sasaki M; Imamura Y; Daimaru Y; Ohdan H; Nakamitsu A
World J Gastroenterol; 2015 Feb; 21(6):1982-8. PubMed ID: 25684967
[TBL] [Abstract][Full Text] [Related]
11. Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases.
Yuzhalin AE; Lim SY; Gordon-Weeks AN; Fischer R; Kessler BM; Yu D; Muschel RJ
Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G625-G639. PubMed ID: 31545917
[TBL] [Abstract][Full Text] [Related]
12. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
Beppu T; Hayashi N; Masuda T; Komori H; Horino K; Hayashi H; Okabe H; Baba Y; Kinoshita K; Akira C; Watanebe M; Takamori H; Baba H
Anticancer Res; 2010 Mar; 30(3):1015-20. PubMed ID: 20393029
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
[TBL] [Abstract][Full Text] [Related]
15. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
Dexiang Z; Li R; Ye W; Haifu W; Yunshi Z; Qinghai Y; Shenyong Z; Bo X; Li L; Xiangou P; Haohao L; Lechi Y; Tianshu L; Jia F; Xinyu Q; Jianmin X
Ann Surg Oncol; 2012 Sep; 19(9):2860-8. PubMed ID: 22526903
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Alberts SR; Horvath WL; Sternfeld WC; Goldberg RM; Mahoney MR; Dakhil SR; Levitt R; Rowland K; Nair S; Sargent DJ; Donohue JH
J Clin Oncol; 2005 Dec; 23(36):9243-9. PubMed ID: 16230673
[TBL] [Abstract][Full Text] [Related]
18. A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Marks E; Rizvi SM; Sarwani N; Yang Z; El-Deiry WS
Cancer Biol Ther; 2015; 16(3):377-82. PubMed ID: 25695537
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection.
Feng WM; Tang CW; Huang SX; Zheng YY; Bao Y; Wang Y; Tao YL
Hepatogastroenterology; 2012 Jun; 59(116):1087-90. PubMed ID: 22328287
[TBL] [Abstract][Full Text] [Related]
20. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
